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RESEARCH ARTICLE
FGF8morphogen gradients are differentially regulated by heparan
sulphotransferases Hs2st and Hs6st1 in the developing brain
Wai-Kit Chan, David J. Price and Thomas Pratt
ABSTRACT
Fibroblast growth factor (FGF) morphogen signalling through the
evolutionarily ancient extracellular signalling-regulated kinase/mitogen
activated protein kinase (ERK/MAPK) pathway recurs in many neural
and non-neural developmental contexts, and understanding the
mechanisms that regulate FGF/ERK function are correspondingly
important. The glycosaminoglycan heparan sulphate (HS) binds to
FGFs and exists in an enormous number of differentially sulphated
forms producedby the action ofHSmodifying enzymes, and sohas the
potential to present an extremely large amount of information in FGF/
ERK signalling. Although there have beenmanystudies demonstrating
that HS is an important regulator of FGF function, experimental
evidence on the role of the different HS modifying enzymes on FGF
gradient formation has been lacking until now. We challenged ex vivo
developing mouse neural tissue, in which HS had either been
enzymatically removed by heparanase treatment or lacking either the
HS modifying enzymes Hs2st (Hs2st−/− tissue) or Hs6st1 (Hs6st1−/−
tissue), with exogenous Fgf8 to gain insight on how HS and the
function of these two HSmodifying enzymes impacts on Fgf8 gradient
formation from an exogenously supplied source of Fgf8 protein. We
discover that two different HS modifying enzymes, Hs2st and Hs6st1,
indeed differentially modulate the properties of emerging Fgf8 protein
concentration gradients and the Erk signalling output in response to
Fgf8 in living tissue in ex vivo cultures. Both Hs2st and Hs6st1 are
required for stable Fgf8 gradients to form as rapidly as they do in wild-
type tissue while only Hs6st1 has a significant effect on suppressing
the levels of Fgf8 protein in the gradient compared to wild type.
Next we show that Hs2st and Hs6st1 act to antagonise and agonise
the Erk signalling in response to Fgf8 protein, respectively, in ex
vivo cultures of living tissue. Examination of endogenous Fgf8
protein and Erk signalling outputs in Hs2st−/− and Hs6st1−/−
embryos suggests that our ex vivo findings have physiological
relevance in vivo. Our discovery identifies a new class of
mechanism to tune Fgf8 function by regulated expression of
Hs2st and Hs6st1 that is likely to have broader application to the
>200 other signalling proteins that interact with HS and their
function in neural development and disease.
KEY WORDS: Heparan sulphotransferase, Hs2st, Hs6st1, Erk, Mapk,
Neural development, Telencephalon, Fibroblast growth factors,Mouse
INTRODUCTION
Fibroblast growth factors (FGFs) are secreted signalling proteins
that function as morphogens by forming protein concentration
gradients emanating from focal sources to elicit dose-dependent
outcomes (Itoh and Ornitz, 2004; Guillemot and Zimmer, 2011).
The broad functional importance and evolutionarily antiquity of
FGFs in neural development implies that molecular mechanisms
regulating FGF morphogen gradients must be both robust and
flexible – robust to reproducibly generate brains during
embryogenesis, yet flexible to allow context-specific function as
well changes to neural molecular biology over evolutionary
timescales. To these ends, could context-specific FGF regulators
act on relatively invariant core system FGF signalling components,
FGF proteins, and their receptors?
The classic ‘source-sink’ model uses differential equations to
describe how steady-state protein concentration gradients, formed
by protein spreading from a focal source through cell fields, require
simultaneous diffusion through the tissue, and clearance (the sink)
from the tissue. According to the model, reaching a steady-state
protein concentration gradient is key for the interpretation of the
gradient by cells (Crick, 1970). FGF protein gradients elicit
intracellular response when FGFs bind cell surface FGF receptors
(FGFRs) to trigger the intracellular extracellular signal regulated
kinase/mitogen activated protein kinase (ERK/MAPK) pathway,
culminating in activating phosphorylation (ERK→pERK). The
negatively charged heparan sulphate (HS) glycosaminoglycan is a
component of cell surface and extracellular matrix (ECM) heparan
sulphate proteoglycans (HSPGs). HS is well placed to play
regulatory roles in FGF gradient formation and signalling by
binding FGFs in the ECM and as an obligate FGF co-receptor in
ternary FGF:FGFR:HS signalling complexes (Carlsson and Kjellen,
2012; Bülow and Hobert, 2004). HS promiscuously restricts net
spreading of FGFs (Fgf2, Fgf4, Fgf8, and Fgf10) by hindering
diffusion and modulating the receptor-mediated endocytosis (RME)
mediated sink by binding FGFs to the cell surface (Shimokawa
et al., 2011; Muller et al., 2013; Schlessinger et al., 2000; Loo and
Salmivirta, 2002; Ornitz et al., 1992; Allen and Rapraeger, 2003;
Yu et al., 2009; Qu et al., 2012; Duchesne et al., 2012). HS synthesis
is a multistep enzymatic process where regulating one or more steps
could control FGF morphogen function. The linear [uronic acid –
glucosamine]n HS polymer is synthesised by EXT enzymes and
modified by enzymatic addition and removal of sulphate groups by
heparan sulphotransferases (HSTs) and sulphatases (SULFs),
respectively. HS modifying enzymes underwent evolutionary
expansion from the origin of multicellular animals suggesting a
role in evolving tissue complexity. Mammals have 17 HSmodifying
enzymes classed into five categories (HS3ST, NDST, HS2ST,
HS6ST, and SULF) according to exactly where on the uronic acid–
glucosamine disaccharide residue they add or remove sulphate
groups. Many HS modifying enzymes are expressed in developing
brain, pointing to functional importance in neural developmentReceived 5 September 2017; Accepted 10 November 2017
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(Carlsson and Kjellen, 2012; Kreuger and Kjéllen, 2012; Ori et al.,
2011). Furthermore, a screen of different HS structures prepared in
vitro showed that different HS structures selectively activate Fgf
signalling in Fgf signalling bioassays in cell lines (Guimond and
Turnbull, 1999). Although there have been many studies on the role
of HS in modulating the Fgf signalling gradients, the role of
different HS modifying enzymes is not really understood especially
in the physiological context of living tissue. Regulating FGF
signalling by modulating HS synthesis, for example via EXT
expression, is likely a blunt strategy because promiscuous
interaction of HS with multiple paracrine FGFs and other
signalling proteins incurs risk of off-target effects. Could an
alternative mechanism harnessing differential HS sulphation
generated by differential expression of HS modifying enzymes
deliver more nuanced control of FGF function in developing brain?
Here we investigate this question for two HS modifying enzymes
widely expressed in developing brain that catalyse two distinct
forms of HS sulphation – Hs2st adds sulphate to the carbon atom in
position 2 of uronic acid (2-O HS sulphation), while Hs6st1
sulphates position 6 of glucosamine (6-O HS sulphation). We
turned to the tractable system provided by Fgf8 signalling in the
ventricular zone (VZ) of the cortico-septal boundary (CSB) at the
developing mouse embryonic day (E)14.5 telencephalic midline to
investigate the function of Hs2st and Hs6st1 in Fgf8 gradient
formation, and the Erk response to Fgf8 in living tissue. Severe
developmental phenotypes map to the CSB when FGF8/Fgf8 or HS
are disrupted in humans or mice, indicating their functional
importance in this region (Inatani et al., 2003; Smith et al., 2006;
Suzuki-Hirano and Shimogori, 2009; Chan et al., 2015; Mason,
2007; Tornberg et al., 2011; Johnson et al., 2004). Hs2st−/− and
Hs6st1−/− embryos exhibit hyperactive Erk signalling triggering
precocious glial guidepost cell migration from the VZ to ectopic
midline positions where they subsequently misdirect corpus callosal
axons, a phenotype linked to elevated Fgf8 levels in Hs6st1−/− but
notHs2st−/− embryos (Clegg et al., 2014; Conway et al., 2011). This
work prompts the hypothesis that Hs2st and Hs6st1 differentially
regulate Fgf8 function. Herewe employ quantitative ex vivo analysis
and, consistent with this hypothesis, show that Hs2st and Hs6st1
each exert significantly different control over the emergence of a
steady-state Fgf8 protein concentration gradient and the intracellular
pErk response to Fgf8 in living tissue.
RESULTS
Ex vivo assay for Fgf8 gradient formation
Fgf8 gradient formation involves the production of Fgf8 at the
source, followed by Fgf8 transport through the extracellular matrix
in the tissue, activation of the signalling pathway through receptor
binding of responding cells, and finally Fgf8 protein clearance. The
emergence of the Fgf8 protein gradient could be modulated by HS
modifying enzymes at any step of the pathway. Dissecting the role
of Hs2st and Hs6st1 in Fgf8 gradient formation modulation in vivo
is difficult as there are many variables that are not tenable to
experimental control, such as the amount of Fgf8 protein emanating
from the source. Therefore, we designed an ex vivo bead assay in
which we challenged slices of embryonic forebrain in which HSwas
enzymatically removed (Heparanase treatment) or lacking
functional HS modifying enzymes Hs2st (Hs2st−/− tissue) or
Hs6st1 (Hs6st1−/− tissue) with a constant amount of Fgf8 to probe
the formation of a Fgf8 protein gradient through time. The ex vivo
assay allowed us to probe Fgf8 gradient emergence in much smaller
timescales, that is impossible to assay in vivo, providing a higher
temporal resolution of Fgf8 gradient formation.
In E14.5 mouse telencephalon, Fgf8 mRNA expression is
restricted to the angle between the cerebral cortex and the septum
at the CSB, identifying this region as the source of Fgf8 protein in
vivo (Fig. 1A, arrowhead marks angle). We recreated this
configuration ex vivo by embedding beads infused with
recombinant Fgf8 protein (or BSA control) into the VZ at the
CSB angle of telencephalic midline tissue explants (dissected
region indicated by red dashed line in Fig. 1A and red shading in
schematic in Fig. 1B, arrowheads marks angle). Explants were
cultured for 1-4 h to allow Fgf8 protein to spread from the bead into
the surrounding living tissue, after which explants were fixed and
sectioned, reacted for Fgf8 immunofluorescence, imaged, and
IMAGEJ used to quantify how Fgf8 protein concentration ([Fgf8])
varies with distance (d ) from the Fgf8-bead edge (Fig. 1C; Fig. S1).
Hs2st and Hs6st1 differentially regulates Fgf8 gradient
formation ex vivo
When wild-type (WT) tissue was challenged with an Fgf8-soaked
bead, the concentration of Fgf8 protein ([Fgf8]) is highest closest to
the Fgf8-bead and decays with increasing distance from the bead
edge (Fig. 1D). Plotting [Fgf8] [expressed as arbitrary units (AU)]
in the tissue against distance from the bead at each time-point
produces classic decay curves with [Fgf8] falling non-linearly with
increasing distance from the bead. Comparison of these curves
shows no change over the 1-4 h period, indicating that a steady state
gradient is achieved <1 h after introducing the Fgf8-bead into the
tissue [Fig. 1H – note superimposition of black (1 h), red (2 h), and
blue (4 h) lines]. A Kolmogorov–Smirnov (KS) test was used to
compare WT spatial concentration curves over 1-4 h revealing no
statistically significant differences for anyWT-WT comparison, and
confirming that the gradient reaches a steady-state before 1 h
(Table S1A). Note these experiments only measure Fgf8
exogenously supplied by the bead; we did not detect any
endogenous Fgf8 in the slices as no Fgf8 signal was detected in
the BSA bead controls (green lines in Fig. 1H-K). We suspect that
the endogenous Fgf8 in the slices were cleared during slice
preparation when slices were incubated in recovery medium for >1 h
prior to bead implantation. Next we assessed the role of HS and the
activity of Hs2st and Hs6st1 on the [Fgf8] gradient over time by
removing HS (pre-treating WT tissue with heparanase) or using
tissue from Hs2st−/− or Hs6st1−/− embryos. Representative images
of Fgf8 immunofluorescence show that these three conditions
resulted in an unstable [Fgf8] gradient that does not achieve the WT
steady state between 1 and 4 h (compare [Fgf8] between time-points
in Fig. 1E-G). The [Fgf8] gradient of each condition also deviated
fromWT [Fgf8] (compare [Fgf8] in Fig. 1D to those in E-G at each
time-point).
In heparanase-treated, Hs2st−/−, and Hs6st1−/− experiments, in
contrast to WT, there were multiple significant differences between
the gradients at successive time-points (shown as t, Fig. 1M-O; KS
test P-values for within condition comparisons between spatial
concentration curves listed in Table S1A) indicating impaired
ability for forming a steady state [Fgf8] gradient. There were also
significant deviations from the WT [Fgf8] gradient, although here,
heparanase-treated, Hs2st−/−, and Hs6st1−/− experiments showed
different effects. Following heparanase treatment, the spatial
concentration curve was higher than WT after 1 h and then
dropped rapidly, becoming lower than WT by 2 h and barely
detectable after 4 h, all of these differences were significant. Both
Hs2st−/− and Hs6st1−/− tissue also formed non-steady-state [Fgf8]
gradients. However it is important to note that the [Fgf8] gradient in
Hs2st−/− tissue was not significantly different to the WT [Fgf8]
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gradient after 4 h in culture, although the [Fgf8] gradient fluctuated
in the earlier time-points. The spatial concentration curve formed in
Hs2st−/− tissue was significantly higher than WT after 1 h, lower
than WT after 2 h, and not significantly different to WT after 4 h
(Fig. 1J). On the other hand, the [Fgf8] gradient in Hs6st1−/− tissue
remained higher than the WT gradient from the second time-point
and throughout the culture. The spatial concentration curve formed
in Hs6st1−/− tissue was not significantly higher than WT after 1 h,
but then became much higher at 2 h and then fell, but remained
significantly higher than WT by 4 h (Fig. 1K).
Fig. 1. See next page for legend.
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These data demonstrate that the formation of a steady-state [Fgf8]
gradient over a 4 h time period is sensitive to the presence of HS
(heparanase experiment) (Fig. 1E,I,M,Q), and to Hs2st and Hs6st1
activity (Hs2st−/− andHs6st1−/− experiments) (Fig. 1F,G,J,K,N,O,R,S).
Hs2st and Hs6st1 regulates formation of a stable Fgf8
gradient via modulation of [Fgf8] amplitude but not [Fgf8]
decay
The [Fgf8] gradient is determined by three independent factors:
[Fgf8] at the source; the amount of Fgf8 protein in the gradient (the
amplitude); and the rate at which [Fgf8] decays with increasing
distance from the source (the decay). In these experiments [Fgf8] at
the source is constant (see below). We next asked whether the HS
manipulations contribute to changing the [Fgf8] gradient by
modulating its amplitude, decay, or both.
We calculated the amplitude of the [Fgf8] gradient from the area
under the curves in Fig. 1H-K and presented the amplitude variation
with time in Fig. 1L-O. Statistical comparisons were made to assess
whether amplitude achieved steady state and deviated from WT
(two-way ANOVA followed by post hoc Holm-Sidak test; P-values
for these pair-wise comparisons listed in Table S1B). Comparing
[Fgf8] amplitude between time-points of each condition, the
amplitude of WT tissue remained constant over time with no
significant differences, indicating a steady-state amplitude was
achieved as early as 1 h of culture (Fig. 1L). In contrast, there are
significant differences between some time-points in heparanase-
treated,Hs2st−/−, andHs6st1−/− experiments indicating an impaired
ability to maintain a steady-state Fgf8 amplitude over time (Fig. 1M-O,
cross marks significant differences between time-points). There were
also significant differences in amplitude when comparing HS
manipulated cultures to WT cultures (Fig. 1M-O, asterisk marks
time-points where the amplitude is significantly different to WT).
Heparanase treatment resulted in amplitude not significantly
different to WT for the first 2 h followed by a significant drop to
very close to detection threshold (Fig. 1M). We found that the
amplitude fluctuated significantly inHs2st−/− tissue; however, none
of these changes were significantly different to corresponding WT
time-points (Fig. 1N). Nevertheless, the significant difference
between the Hs2st−/− andWT [Fgf8] curves at both 1 and 2 h time-
points suggests that failure to attain a stable [Fgf8] amplitude is
causing significant changes to the [Fgf8] gradient. In contrast,
Hs6st1−/− tissue showed a significant 2.5-fold increase in amplitude
after 2 h, which then fell by 4 h when it was not significantly
different to WT (Fig. 1O).
The decay of a protein gradient is described by different equations
depending on both diffusion kinetics and whether the degradation
rate, for example clearance of Fgf8 by RME, is linear or non-linear
as a function of distance from the source (Wartlick et al., 2009; also
see Discussion). We found that the [Fgf8] spatial distribution in our
experiments behaved as power law gradients, with log[Fgf8] vs log
distance transforming the [Fgf8] vs distance curves to linearity
(R2>0.9, Table S1C); the more negative the slope the more rapid the
[Fgf8] decay as a function of distance (Fig. 1P-S, underlined
numbers to right of each line indicate average slope values).
Statistical comparison of the slopes showed that there were no
significant differences between WT and any HS condition at any
time-point (Table S1C), indicating that none of the HS
manipulations described here have a significant impact on [Fgf8]
decay as a function of distance from the source. Interestingly,
although the gradient of Hs6st1−/− was significantly different from
WT at the 4 h time-point, neither the [Fgf8] amplitude or [Fgf8]
decay (slope in Fig. 1S) of the 4 h time-point was significantly
different from WT. In addition, we also observed this phenomenon
with the Hs2st−/− [Fgf8] gradient curves at the 1 and 2 h time-
points. Presumably, both are contributing to affect the Fgf8 gradient
with neither contribution reaching statistical significance. We also
noted that although the Hs6st1−/− slopes were found to be not
significantly different between different time-points, there is a trend
that the Hs6st1−/− slopes between time-points were not parallel
(Fig. 1S). This was only observed in theHs6st1−/− slices asHs2st−/−
and WT slices have parallel slopes between different time-points
(compare Fig. 1S with Fig. 1P-R), while slopes for heparanase
treated slices were not parallel due to the lack of an Fgf8 gradient
after 4 h in culture. The log[Fgf8] intercept, obtained by
extrapolation (dotted lines in Fig. 1P-S, numbers on the log[Fgf8]
axis indicate average intercept values), gives [Fgf8] at the source
which is the surface of the Fgf8 bead (<1 µm from bead edge), and
there were no significant differences (two-way ANOVA flowed by
post hoc Holm-Sidak testing of pairwise comparisons, Table S1D)
except between WT and heparanase treated tissue at the 4 h time-
point. This indicates the bead [Fgf8] was constant in all conditions
and time-points (except heparanase treated cultures after 4 h). This
was confirmed by direct quantification of bead [Fgf8] (Fig. S1E), so
bead [Fgf8] was not a variable contributing to differences observed
between other conditions and time-points.
To conclude, the rapid (<1 h) formation of a steady state [Fgf8]
gradient in WT tissue is dependent on the presence of HS and the
activity of HSmodifying enzymes Hs2st and Hs6st1. The formation
of [Fgf8] steady-state gradient can be primarily attributed to a role
for HS in controlling the amount Fgf8 protein present in the
concentration gradient ([Fgf8] amplitude), as opposed to
modulating the decay of Fgf8 as a function of distance from the
source ([Fgf8] decay). Critically, our analysis found that Fgf8
behaved differently in living Hs2st−/− and Hs6st1−/− tissue with a
much stronger effect in Hs6st1−/− tissue, indicating that the Hs6st1
plays the dominant role in supressing Fgf8 levels.
Hs2st and Hs6st1 differentially regulates pErk response to
the Fgf8 protein gradient ex vivo
The binding of Fgf8 to its receptor activates the phosphorylation of
Erk. As HS also functions as an Fgf co-receptor, we next
Fig. 1. Differential HS sulphation regulates [Fgf8] gradient formation with
differential kinetics. (A) Fgf8mRNA is located at the CSB angle (arrowhead).
This image is also shown enlarged in Fig. 3C. Sep, septum; Ctx, cortex; GE,
ganglionic eminences. (B) Schematic of ex vivo explant culture with Fgf8-
infused bead implanted at the CSB angle (arrowhead). (C) Fgf8
immunofluorescence (here shown as greyscale) illustrating concentric rings
(yellow) used to quantify [Fgf8] at increasing distance (d) from the Fgf8-bead
edge. (D-G) Representative images of Fgf8 immunofluorescence (red) in
sections though cultured explants under different conditions and time-points
indicated next to panels, asterisk marks bead centre. (H-K) [Fgf8] gradient up
to 200 µm from the bead. Data for 1, 2, and 4 h time-points coloured black, red,
and blue respectively with BSA control data coloured green, asterisks indicate
significant difference between each particular condition with its corresponding
WT (Kolmogorov–Smirnov test; P<0.05 following a Bonferroni correction for
multiple pairwise comparisons). (L-O) Total Fgf8 level within 200 µm of the
bead. Cross indicates significant differences between bracketed time-points
within a culture condition indicating fluctuating amplitude through time, while
asterisks indicate significant difference at a particular time-point between each
particular condition andWT (two-way ANOVA followed by Holm-Sidak post hoc
test; P<0.05). (P-S) Fitted curve of H-I in log10[Fgf8] vs. log10[d]. Each plot
shows all data points and average line of best fit (solid line) with dotted line
indicating extrapolation to log10[Fgf8] axis with numbers on indicating intercept
and underlined numbers the slope. Number of explants analysed (N): WT, 8;
Heparanase, 5; Hs2st−/−, 5; Hs6st1−/−, 4. Scale bar in D applies to D-G:
100 µm. In H-S values are shown as mean±s.e.m.
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investigated how HS, Hs2st and Hs6st1 regulated the Erk response
to the Fgf8 gradient (Fig. 1B). All sections reacted for Fgf8
immunofluorescence (Fig. 1, red) were simultaneously reacted for
pErk immunofluorescence (Fig. 2, green). InWT cultures, pErk forms
a gradient with the highest concentration of pErk ([pErk]) closest to
the bead (Fig. 2A show representative images with gradient
quantification in Fig. 2E). There is a marked drop in the [pErk]
gradient after 4 h (red=black>>blue lines in Fig. 2E; Table S2). Our
analysis quantifies both Fgf8 and pErk signals at each distance from
the Fgf8-bead, and these values were combined in a [pErk] (y-axis)
vs [Fgf8] (x-axis) plot to generate a dose response curve showing the
pErk response elicited by different [Fgf8] in the tissue (Fig. 2I). The
[Fgf8]/[pErk] dose response is stable for the first 2 h, but after 4 h the
cells becomes much less sensitive with saturating levels of Fgf8
eliciting ∼60% the pErk output of the earlier time-points
(blue<red=black lines in Fig. 2I).
Fig. 2. Differential HS sulphation differentially regulate Erk response to Fgf8. (A-D) Representative images of pErk immunofluorescence in sections
though cultured explants representing different conditions and time-points indicated on panels, asterisk marks bead centre. (E-H) [pErk] gradient formed at
different time points up to 200 µm from the bead. Asterisks indicate significant difference between each particular condition with its corresponding WT
[Kolmogorov–Smirnov test (P<0.05) following a Bonferroni correction for multiple pairwise comparisons]. (I-L) [Fgf8]/[pErk] dose response curves.
Number of explants analysed:WT, 8; Heparanase, 5; Hs2st−/−, 5; Hs6st1−/−, 4. Data for 1, 2, and 4 h time-points coloured black, red, and blue respectively.
Scale bar in D applies to A-D: 100 µm. In E-L values are shown as mean±s.e.m.
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Eliminating HS altogether (heparanase treatment) significantly
reduces the [pErk] gradient compared to WT at all time-points
(Fig. 2B shows representative images with pErk distribution curves
in Fig. 2F, asterisk marks two-way ANOVA followed by post hoc
Holm-Sidak test P<0.05), and the [Fgf8]/[pErk] dose response
shows strong de-sensitisation to Fgf8 (Fig. 2J). In contrast, loss of
Hs2st or Hs6st1 in Hs2st−/− or Hs6st1−/− tissue, respectively, has a
weaker effect on the [pErk] distribution curve, but tellingly each had
a distinct effect on the [Fgf8]/[pErk] dose response. In Hs2st−/−
cultures, a substantial pErk response surrounding the bead is
detectable at all time points (Fig. 2C) and the [pErk] gradient
increases with time in culture and differs significantly fromWT after
4 h (black<red<<blue line in Fig. 2G, asterisk marks two-way
ANOVA followed by post hoc Holm-Sidak test P<0.05). The [Fgf8]/
[pErk] dose response shows that Hs2st−/− tissue becomes
progressively more sensitive to Fgf8 over time (black<red<blue line
in Fig. 2K). A completely different phenotype occurs in Hs6st1−/−
cultures (Fig. 2D) where the [pErk] gradient is similar across all
time points (black=red=blue lines in Fig. 2H) and not significantly
different to WT. The [Fgf8]/[pErk] dose response shows that
Hs6st1−/− tissue is de-sensitised to Fgf8 and saturating doses of
Fgf8 only elicited ∼60% of the pErk response ofWT cultures after 1
and 2 h (compare Fig. 2I to L). We conclude that HS facilitates the
pErk response to Fgf8 while Hs2st and Hs6st1 have complementary
functions by negatively and positively modulating the [Fgf8]/
[pErk] dose response respectively.
Hs2st and Hs6st1 differentially regulates Fgf8 and pErk
in vivo
The ex vivo experiments showed us how living tissue reacts when
challenged with an implanted bead acting as an experimentally
introduced source of Fgf8, likely at non-physiological levels. HS
was found to be critical for [Fgf8] gradient formation and the Erk
response to Fgf8 as the loss of HS resulted in no detectable [Fgf8]
gradient after 4 h in culture and loss of Erk response to Fgf8. Hs2st
was found to play a minor role in the maintaining a stable Fgf8
gradient as removal of Hs2st resulted in [Fgf8] fluctuations during
[Fgf8] gradient formation before eventually reaching WT [Fgf8]
levels, albeit taking a longer time than WT tissue. Meanwhile,
Hs6st1was found to be needed to suppress [Fgf8] during the [Fgf8]
gradient formation. The ex vivo experiments also showed that Hs2st
antagonises the Erk response to Fgf8, while Hs6st1 is needed to
promote Erk response to Fgf8.
Do the principles we have established ex vivo for the differential
control exerted by Hs2st and Hs6st1 on the Fgf8 protein
concentration gradient and the pErk response it elicits apply in
vivo? In order to address this, we examined the expression of Hs2st,
Hs6st1, Fgf8, Fgfr1, and pErk in the CSB region of E14.5 WT,
Hs2st−/−, andHs6st1−/− embryos.Hs2st andHs6st1 are expressed at
relatively high levels in the VZ at the CSB angle (black arrowheads
in Fig. 3A,B). Note that compared to their high expression at the
CSB angle, Hs2st is expressed at much lower levels in lateral
telencephalon (Fig. 3A) and Hs6st1 is expressed at much lower
levels in the area marked with a cross in Fig. 3B. There is no gross
difference in Fgf8 mRNA distribution between WT, Hs2st−/−, or
Hs6st1−/− CSB (Fig. 3C-E), indicating any differences in Fgf8
protein distribution between genotypes stems from post-
transcriptional regulation. Fgf8 protein is found at low levels in
the WT VZ, predominantly at the apical surface, and is more
abundant at the midline (Fig. 3F with higher magnification of VZ in
I). Fgf8 protein is increased at the Hs2st−/− midline VZ (Fig. 3G
with higher magnification of VZ in J). By far the strongest effect on
Fgf8 protein distribution is seen in Hs6st1−/− CSB where, in
addition to an increase at the midline and expansion into the septum
(arrow in Fig. 3H), there is much stronger staining throughout the
VZ (Fig. 3Hwith higher magnification of the VZ in K). Quantifying
the fluorescence intensity of Fgf8 immunofluorescence of the VZ of
the CSB (Fgf8 signal quantified in a 100 µm×180 µm box placed
over the CSB encompassing area shown in Fig. 3I-K) enabled us to
measure the [Fgf8] at the CSB in vivo. We found that there was a
statistically significant threefold increase of Fgf8 fluorescence in
Hs6st1−/− tissue; however, there was no statistically significant
increase in the Hs2st−/− tissue compared to WT (Fig. 3L). These
results correlated with the ex vivo results previously obtained
(Fig. 1), in which Hs6st1 plays a more significant role on [Fgf8]
gradient amplitude regulation thanHs2st at the VZ of the CSB. How
do the changes in Fgf8 protein in Hs2st−/− and Hs6st1−/− embryos
impact on the pErk response? The pErk levels are higher in both
Hs2st−/− and Hs6st1−/−mutants than in the WT (Fig. 3Q-S with
higher magnification of the VZ shown in T-V). The intensity of
pErk (Hs2st−/−=Hs6st1−/− >WT, Fig. 3Q-S) staining does not reflect
the levels of Fgf8 protein (Hs6st1−/− >Hs2st−/− WT, Fig. 3F-L)
indicating that WT, Hs2st−/−, and Hs6st1−/− tissue is differentially
sensitive to Fgf8. These observations can be reconciled if Hs2st−/−
tissue is more sensitive to Fgf8 andHs6st1−/− tissue is less sensitive
to Fgf8 to that of WT tissue, respectively, as we observed in our ex
vivo experiments (Fig. 3M, also see Discussion). The similar
expression of Fgfr1, the principal Fgf8 receptor in this region,
between the three genotypes (Fig. 3N-P), indicates differential Fgf8
sensitivity in the VZ is not caused by differential Fgfr1 expression.
The lack of Fgfr1 in the septum (arrow in Fig. 3P) likely explains
why Erk is not activated in the Hs6st1−/− septum (arrow in Fig. 3S)
despite ectopic Fgf8 in this area (arrow in Fig. 3H).
DISCUSSION
A general property of HS is reported in other systems retarding the
net spread of FGFs through tissue (Shimokawa et al., 2011;
Schlessinger et al., 2000; Ornitz et al., 1992; Allen and Rapraeger,
2003; Yu et al., 2009; Qu et al., 2012; Loo and Salmivirta, 2002;
Muller et al., 2013; Duchesne et al., 2012). Our heparanase
experiments indicate this is likely the case in our system because
removing HS causes an initial surge of Fgf8 protein from the Fgf8-
bead into surrounding tissue, followed by depletion of Fgf8 from the
bead and declining Fgf8 concentration. The main conceptual
advance of this study is identifying specific roles for different HS
modifying enzymes in [Fgf8] gradient formation and function as in
WT tissues, the time taken to achieve a steady-state gradient is less
than 1 h while it took about 4 h to achieve WT [Fgf8] gradient in
Hs2st−/− and more than 4 h for Hs6st1−/− tissues, respectively.
The formation of a steady state protein concentration gradient
requires the balancing of three factors: concentration at the source;
diffusion through the tissue; and degradation in the tissue. In our ex
vivo experiments, the source (the Fgf8-bead) provided a constant
[Fgf8], so the effects we describe can be attributed to perturbations
on Fgf8 diffusion and/or degradation. [Fgf8] varies with distance
from the source as a power law gradient, a model describing the
distribution of a protein diffusing from a source and being cleared
from the tissue in a concentration-dependent manner, for example
higher Fgf8 concentrations causing increased Fgf8 degradation
through an Fgf8-sensing feedback mechanism (Wartlick et al.,
2009). We find HS and its sulphation by Hs2st and Hs6st1 are
essential for the normal formation and maintenance of a steady-state
[Fgf8] gradient, because removing HS altogether (heparanase
experiment) or leaving HS intact but losing the function of different
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HS modifying enzymes (Hs2st−/− and Hs6st1−/− experiments) all
caused significant fluctuations in the gradient amplitude (amount of
Fgf8 in the gradient) through time that were not observed in WT
cultures. Although the fluctuations in Fgf8 gradient amplitude
observed in both Hs2st−/− and Hs6st1−/− tissue were significant, we
observed an initial surge in amplitude at the 1 h time-point in
Hs2st−/−, while the surge was only observed in the 2 h time-point in
Hs6st1−/−. The Fgf8 amplitude of both mutant tissues reached WT
levels after 4 h in culture. This prompted the question of whether the
differences we observed in the Fgf8 gradient formation and the Erk
response to the Fgf8 gradient due to the loss of Hs2st and Hs6st1
was due to a timing issue of when steady state is achieved, or that
Hs2st and Hs6st1 have fundamentally different roles in the process
of establishing the Fgf8 gradient and the Erk response. Analyses of
the Fgf8 bead cultures for a longer time period would give further
insight into this question, however culturing explants with Fgf8
beads for periods longer than our current study is not viable as Fgf
molecules have a relatively short half-life. For example, Fgf10
(which is structurally similar to Fgf8) has a half-life of ∼5 h. This
is supported by other studies which performed similar Fgf bead
assays using similar time-frames as this study (Harada et al., 2009;
Qu et al., 2012). Therefore, bead depletion due to the short half-life
of Fgf8 would be a factor affecting the interpretation of results.
Furthermore, as discussed above, we have shown that Fgf8 bead
depletes to ∼50% in explants that lacks HS in 4 h of culture
showcasing the requirement for HS in Fgf8 stability and the short
half-life of Fgf8 (Fig. S1E). In contrast to amplitude, the [Fgf8]
decay, revealed by the slope of log [Fgf8] vs log distance power
function plots, was not significantly altered by removing HS or
losing the function of Hs2st or Hs6st1. This indicates that the
mechanism regulating the decay of Fgf8 as a function of distance
from the source, including feedback mechanisms regulating decay,
were not significantly affected by loss of Hs2st or Hs6st1 function.
Net [Fgf8] decay is determined both by rates of diffusion and
degradation and dissecting the regulation of each component,
particularly by Hs6st1 which has the greater effect on Fgf8
concentration, is a topic for future research.
Interestingly, we found thatWT tissues form a steady-state [Fgf8]
gradient in <1 h when challenged with an exogenous Fgf8 bead.
While the loss of Hs2st affected [Fgf8] amplitude stability (Fig. 1N)
and loss of Hs6st1 caused increased [Fgf8] amplitude (Fig. 1O), we
noticed that bothHs2st−/− andHs6st1−/− tissues challenged with an
Fig. 3. Analysis of Fgf8/Erk signalling components in the CSB region of E14.5.WT, Hs2st−/−, and Hs6st1−/− embryos show correlation to Hs2st and Hs6st1
action ex vivo. (A) Hs2st and (B) Hs6st1 expression visualized by LacZ staining of Hs2stLacZ/+ and Hs6st1LacZ/+ sections, respectively. Cross marks an area with
very low Hs6st1LacZ expression, N=4. (C-E) Fgf8 mRNA expression. N=5. Note that the image in C is an enlargement of that shown in Fig. 1A. (F-H) Fgf8
protein expression. N=3. (I-K) Higher magnification of VZ angle in F-H. (L) Quantification of Fgf8 fluorescent intensities in I-K. P values are as depicted on graph.
Error bars indicate standard error of mean. (M) Dose response ofWT,Hs2st−/−,Hs6st1−/− tissue showing increased sensitivity to Fgf8 inHs2st−/−whileHs6st1−/−
tissue have decreased sensitivity to Fgf8 when compared to WT tissue. (N,O) Expression of Fgfr1 protein. N=4 for WT, N=3 for Hs2st−/− and Hs6st1−/−.
(Q-S) pErk protein expression. N=3. (T-V) Higher magnification of ventricular zone in Q-S. In A, B, C-K and N-V arrowheads indicate apical surface of the
ventricular zone at the CSB angle; arrows in H, P, S indicate Fgf8High, Fgfr1Low, pErkLow septal area inHs6st1−/− embryos.N=3. Ctx, cortex; LGE, lateral ganglionic
eminence; MGE,medial ganglionic eminence; Sep, septum. Scale bars: A applies also to B: 200 µm; C applies to C-E: 100 µm; F applies to F-H: 100 µm; I applies
to I-K: 100 µm; N applies to N-P: 100 µm; and Q applies to Q-S: 100 µm; T applies to T-V: 100 µm.
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Fgf8 bead eventually approached WT levels of [Fgf8] amplitude
(compare Fig. 1N,O to L 4-h time points). This suggests that for a
given dose of Fgf8 input, the CSB tissue tissues must have an
inherent [Fgf8] gradient it tries to achieve, and Hs2st and Hs6st1
each play different roles in the kinetics of achieving this. This also
highlights the damaging loss of control that comes with the loss of
Hs2st or Hs6st1 in modulating the timely formation of the Fgf8
gradient, which is critical in a developmental context as information
from a morphogen gradient needs to be delivered in the correct
developmental time frame. In line with its FGF co-receptor function,
we find HS is a pre-requisite for pErk response to Fgf8 (Loo and
Salmivirta, 2002; Schlessinger et al., 2000; Pellegrini et al., 2000).
Hs2st and Hs6st1 each have more subtle and complementary roles in
the [Fgf8]/[pErk] dose response. Presumably Hs6st1 and Hs2st are
able to function as Fgf8/Erk signalling agonists and antagonists,
respectively, through opposing impacts of Hs2st and Hs6st1
catalyzed HS sulphation on the Fgf8:Fgfr1:HS signalling complex.
Our finding that Hs6st1 facilitates Fgf8 signalling while repressing
Fgf8 levels suggests the hypothesis that Hs6st1-mediated affinity of
Fgf8 for the cell surface promotes both clearance by RME and
signalling activity, possibly also hindering diffusion, through the
common mechanism of stabilising Fgf8:Fgfr1:HS complex
formation. It is important to note that there was no difference in
the Fgfr1 expression between Hs2st−/− and Hs6st1−/− with WT
(Fig. 3N-P), suggesting that the difference in pErk found in Hs2st−/−
and Hs6st1−/− (Fig. 3Q-S) are driven by the co-receptor function of
HS, which in turn is differentially regulated by Hs2st and Hs6st1.
Our ex vivo experiments revealed that Hs2st−/− CSB has
difficulty maintaining a stable [Fgf8] gradient and increased Erk
sensitivity to Fgf8, whileHs6st1−/−CSB has significantly increased
Fgf8 levels compared to WT and decreased Erk sensitivity to Fgf8.
These observations are broadly consistent with our in vivo
observations at E14.5 where Fgf8 protein levels were elevated in
Hs6st1−/− (but not Hs2st−/−) CSB in addition to higher Erk
activation when compared toWT. However, this higher Erk activation
was not much higher than the Erk activation in Hs2st−/− tissue. We
reasoned that the increase in Erk activation found in Hs6st1−/− tissue
in vivowas due to the increased levels of Fgf8 (∼threefold increase)
found in vivo (Fig. 3L), despite the tissue being less sensitive to
Fgf8. This is also consistent to our previous study at E16.5, where
increased Fgf8 protein was only detected in Hs6st1−/− CSB (Clegg
et al., 2014).
In the case of Erk sensitivity to Fgf8, the observed ex vivo
phenotype anticipated the in vivo Hs2st−/− and Hs6st1−/−
molecular phenotype in E14.5 telencephalic midline in which,
despite Hs2st−/− having a less Fgf8 protein than Hs6st1−/− VZ,
both shared a rather similar elevation in [pErk] relative to WT.
This uncoupling of the correlation between [Fgf8] and [pErk] is
reconciled by our ex vivo finding that Hs2st−/− cells are
sensitised to Fgf8 while Hs6st1−/− cells are desensitised
(Fig. 3M). Using the dose response curve, we can estimate the
level of Erk activation of the tissue when presented with a known
amount of Fgf8. In the case of Hs6st1−/− tissue, we can clearly
see that a fourfold increase of Fgf8 in Hs6st1−/− when compared
to WT would result in higher Erk activation compared to WT,
even though the sensitivity of Hs6st1−/− cells to Fgf8 are lower
compared to WT corroborating our observation in vivo (Fig. 3M).
While it is difficult to exclude the possibility that other FGF and
non-FGF proteins signalling through pErk also contribute to the
Hs2st−/− and Hs6st1−/− phenotypes, our data show that perturbing
the Fgf8/Erk axis makes a major contribution to the observed
molecular phenotypes.
It is well known that loss of specific HS sulphation causes
compensatory effects. It has been previously shown in Drosophila
that loss of 2-O sulphation causes compensatory increases in 6-O
sulphation and vice versa, contributing to Fgf signalling in the
trachea (Kamimura et al., 2006). There was also a report of increase
in N-sulphation compensating for loss of 2-O sulphation in Chinese
hamster ovary cells (Bai and Esko, 1996). We have previously
shown that the Hs2st−/− mice used in this study have no
compensatory increase in other sulphation following the loss of 2-
O sulphation (Chan et al., 2015), but the sulphation status of
Hs6st1−/− mice is unknown. However, both ex vivo (Figs 1 and 2)
and in vivo (Fig. 3) results clearly show that any compensation at the
sulphation level in Hs6st1−/− was unable to rescue the increased
[Fgf8] and Erk desensitisation phenotype, providing further
support to the role of differential sulphation in modulating
[Fgf8] gradient and the Erk response to the [Fgf8] gradient.
How the molecular phenotypes of Hs6st1−/− we observed in this
study relates to the HS sulphation status awaits biochemical
analyses. Unfortunately, it is currently extremely challenging to
analyse the sulphation status of tissue as small as our region of interest,
the CSB. Nevertheless, the effects of the loss of Hs2st and Hs6st1
observed in this study shed light on the gene function of Hs2st and
Hs6st1 in modulating Fgf8 gradient and the Erk response to Fgf8 in
the developing telencephalon.
Comparing the consequences of tinkering with overall levels
of HS (heparanase treatment) as opposed to its modification
(Hs2st−/− and Hs6st1−/−) supports the hypothesis that regulating
specific HS sulphation via expression of HS modifying enzymes
provides a more nuanced mechanism to control Fgf8 morphogen
function than globally regulating HS synthesis. Removing HS
effectively shuts down Fgf8 function while removing Hs2st or
Hs6st1 play more modulatory roles. Furthermore, in contrast to the
promiscuous interaction of HS with all paracrine FGFs, we find
that Hs2st and Hs6st1 each have distinct effects on Fgf8 and may
well have similarly specific relationships with other FGFs, and
some of the >200 HS interacting signalling molecules
comprising the heparanome in mammals (Ori et al., 2011). In
any case, it is clear that robustness of Fgf8 morphogen gradient
formation is dependent on appropriate expression of heparan
sulphotransferases, providing a hitherto undemonstrated mechanism
to flexibly regulate Fgf8 signalling post-transcriptionally. Our
discovery establishes a general principle that may well apply
more broadly to other HS sulphation modifications and HS
interacting signalling molecules and so contribute a deeper
understanding of the molecular mechanisms underpinning the
development and evolution of multicellular structures. These
mechanisms introduce heterogeneity into FGF signalling so are
likely a particular asset to the development of a structure as
extremely complex as the mammalian brain.
MATERIALS AND METHODS
Animals
Hs2stLacZ (Hs2st−) and Hs6st1LacZ-IRES-hPLAP (Hs6st1−) mutant
alleles were maintained on a CBA background (Leighton et al.,
2001; Mitchell et al., 2001; Bullock et al., 1998). Genotyping was
performed by as described previously (Pratt et al., 2006; Clegg
et al., 2014). All mice were bred in-house in line with
Home Office UK legislation. The licenses authorising this
work were approved by the University of Edinburgh Review
Committee and the Home Office. Animal husbandry was in
accordance with the UK Animals (Scientific Procedures) Act
1986 regulations.
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Immunochemistry and LacZ staining
Immunohistochemistry (pErk) and immunofluorescence (Fgf8,
pErk, Fgfr1) were performed on ex vivo and in vivo material as
previously described (Clegg et al., 2014; Toyoda et al., 2010).
Primary antibodies: rabbit anti-phospho-MAPK1/2 (1/200)
(D13.14.4E) (Cell Signalling Technology); mouse rabbit
monoclonal antibody anti-Fgf receptor 1 (1/200) (D8E4) (Cell
Signalling Technology); mouse anti-10E4 (1/200) (370255-1)
(Amsbio); anti-Fgf8 mouse monoclonal antibody (1/2500)
(MAB323) (R&D Systems). Secondary antibodies and detection:
Peroxidase-conjugated Affinipure goat-anti-mouse IgG1 (1/1000);
goat anti rabbit Alexa Fluor 488 (1/200) (Invitrogen); and Fgf8
staining was detected via TSA Plus Fluorescence Systems (Perkin-
Elmer). LacZ staining performed as described previously (Pratt
et al., 2006). N≥3 for all genotypes.
Organotypic explant culture
Modification of methods described by López-Bendito et al. (2006)
and Qu et al. (2012). Briefly, explants comprising the CSB region
were dissected from E14.5 telencephalon and placed ventricular
surface up on a floating membrane with a Fgf8-infused (or BSA
control) bead implanted into the CSB angle. WT, Hs2st−/−, or
Hs6st1−/− explants, some of which were pre-treated with Heparanase
(Sigma) for 2 h at 37°C, were cultured for 1, 2, or 4 h prior to fixation,
sectioning (10 µm frozen sections) and processing for Fgf8 and pErk
immunofluorescence and DAPI counterstaining.
Imaging and analysis
Fluorescent sections were imaged using Leica AF6000
epifluorescence microscope connected to a DFC360 camera on
constant exposure settings for three channels, DAPI, Fgf8, and pErk,
and analysed using IMAGEJ. IMAGEJwas used to draw 10-µmwide
regions of interest (ROI) on each image (see Fig. S1 for illustration of
ROI placement) and used to quantify signal intensity at increasing
distances from the edge of the bead into the tissue (for Fgf8 and
pErk gradient quantification) and in the outer edge of the bead (for
Fgf8 only). Data were then combined and graphed using GraphPad
Prism 6 (GraphPad). Images from all genotypes of each time point
experiment were imaged, processed and analysed in parallel to
minimise technical variation for comparison between genotypes of
the same time point. Values from BSA control cultures were
subtracted to remove background fluorescence. Fgf8 fluorescence in
in vivo sections were quantified using IMAGEJ. Quantification of
Fgf8 in vivo: mean fluorescence for boxes of 100×180 µm drawn at
the CSB were obtained for at least 2 sections per embryo with
N being number of embryos analysed. WT, N=4; Hs2st−/−, N=3;
Hs6st1−/−, N=3.
Statistical analysis
Statistical comparisons were made between different tissue
conditions (WT, heparanase treated, Hs2st−/−, and Hs6st1−/−)
and culture durations (1, 2, and 4 h time-points) using
Kolmogorov–Smirnov (KS) test with Bonferroni correction to
compare [Fgf8] and [pErk] gradients and ANOVA followed by
Holm-Sidak post hoc test to compare [Fgf8] amplitude, [Fgf8] at
the bead and slopes of Fgf8 distribution. The Fgf8 and pErk
fluorescence intensity were normalised to the value at the point
closest to the bead of the 1 h time point in WT tissue, which was
designated as 100%. Statistical comparisons were made between
WT, Hs2st−/− and Hs6st1−/− for Fgf8 fluorescence intensity of in
vivo sections using one-way ANOVA followed by Dunnett’s post
hoc test.
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